News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
The Hidden Cost of Disconnected Quality Systems: Why Hospitals Should Modernize Now - MedCity News
The case for modernization isn’t solely about improving efficiency. It’s about equipping hospitals with the resources necessary to manage risk proactively, respond to negative trends quickly, and prioritize patient safety with high reliability.
Hospitals See Financial Gains Due to Higher Volumes & Improved Throughput - MedCity News
Hospitals saw improved financial performance during the first four months of the year, with operating margins rising to 3.3% thanks to higher patient volumes and more efficient throughput. However, experts warn that hospitals remain financially vulnerable as non-labor expenses continue to rise.
How Healthcare Can Reduce Cybersecurity Response Times from Hours to Minutes - MedCity News
When an attack or other issue occurs, the main difference between being down for months versus minutes or a day is having a mature and tested incident response plan. Without a plan, your cybersecurity team is flying blind, resulting in confusion and inefficiency that significantly slows your response time.
J&J’s Growth Strategy in Lung Cancer Borrows From Its Experience in Multiple Myeloma - MedCity News
Johnson & Johnson has projected its lung cancer drug Rybrevant could achieve $5 billion in peak revenue. At the recent ASCO annual meeting, J&J executive Joshua Bauml explained his company’s strategy for this drug in lung cancer and beyond.
INVEST Pitch Perfect Spotlight: How Pear Suite Makes Sure Community Health Workers Get Paid - MedCity News
Pear Suite recently won the payer/provider technology track of MedCity News’ INVEST Pitch Perfect contest. The startup provides a software platform for community health workers that helps them share data, submit claims and maintain compliance.
Debunked Episode 16: Will Trump Administration's Drug Pricing Policies Lead to the End of PBMs? - MedCity News
UH Group replaces its CEO, the payer's alleged nursing home practices, the future of pharmacy benefit managers, and the healthcare implications of the budget bill are part of the latest episode of the Debunked Podcast with MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch.
The Connected Patient Experience: 3 Tips to Empower Healthcare Delivery Through Innovation - MedCity News
Patients no longer want to rely upon only whatever snippets of information they get from their doctor at an annual or semiannual checkup. They’re looking for a fully connected patient experience. Healthcare organizations need to know what that looks like, how to build it, and how they fit into the full picture.
Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds - MedCity News
Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology to its metabolic medicines; the deal follows a similar move Novo Nordisk starting an alliance with Ascendis.
Navigating the AI in Healthcare Landscape and Its Future: A Preview of INVEST Digital Health 2025 - MedCity News
MedCity INVEST Digital Health on September 18 at Pegasus Park in Dallas will explore AI through a series of discussions leading up to our annual Pitch Perfect contest, where healthcare startups pitch their companies to a team of investor judges. Register today!
The GOP’s Budget Plan Is a Crisis in the Making for Hospitals - MedCity News
If enacted, the GOP’s spending bill could kick more than 10 million Americans off Medicaid. Experts are worried about the major spike in uncompensated care that hospitals would have to provide — and they’re warning that this change will result in major revenue losses for hospitals, facility closures, higher premiums for commercially insured patients, and worse public health.
Weathering the Shifting Trial Landscape - MedCity News
This is the moment to build flexible plans. Organizations that develop operational models with built-in scenario planning, ready to scale up or down as the capital environment shifts, will be positioned to take advantage of greater investment when it comes.
Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia - MedCity News
Kura Oncology’s ziftomenib addresses a specific genetic mutation present in about 30% of cases of acute myeloid leukemia. Data from the drug’s pivotal Phase 2 test were presented during the annual meeting of the American Society of Clinical Oncology.
How One Startup Is Aiming to Replace Surgery with Its Endometriosis Diagnostic - MedCity News
Heranova Lifesciences recently launched a noninvasive blood test to diagnose endometriosis. The standard diagnostic method is laparoscopy, which requires anesthesia, followed by histological confirmation. With its blood test, Heranova seeks to replace the diagnostic function of laparoscopy, thus reserving surgical intervention only for therapeutic purposes.
BMS Buys Into BioNTech Bispecific Antibody, Putting Up $1.5B to Collaborate in Multiple Cancers - MedCity News
Bristol Myers Squibb’s partnership with BioNTech makes it the third big pharma company to strike a deal to gain access to a PD-L1/PD-1 and VEGF bispecific antibody with potential use in drug combinations to treat cancer. The deal calls for the two companies to share in the development of BioNTech’s drug and co-commercialize the asset globally.
A Defining Moment for Employer Health Benefits: How the “One Big Beautiful Bill” Could Transform Healthcare for Employers - MedCity News
The "One Big Beautiful Bill" would codify Individual Coverage Health Reimbursement Arrangements (ICHRAs) — the personalized insurance model that has transformed how employers offer health benefits — into law as CHOICE Arrangements, or Custom Health Option and Individual Care Expense arrangements.
Analysis: The No Good, Very Bad Year for UnitedHealth - MedCity News
UnitedHealth Group has had a difficult year marked by a dramatic stock drop, leadership shake-up and mounting regulatory scrutiny. Experts point to its aggressive Medicare Advantage strategy and a rapidly evolving healthcare landscape as key drivers of its challenges.
At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor - MedCity News
Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma. The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology.
CMS's Final Rule Impacting Star Ratings Puts Outcomes In Focus — Are Health Plans Ready to Take Action? - MedCity News
This is a great opportunity to align your strategies with CMS’s evolving framework by refining care models to focus on impact, investing in digital capabilities that support data use, and continuing to build infrastructure that addresses disparities in care.
A Call for Healthcare Cuts — But Not the Kind You’re Thinking Of - MedCity News
What if the kind of cuts we should be talking about are the ones that actually make care better? Like cutting confusion. Because for many people, the biggest barrier to healthcare access isn’t cost or availability – it’s complexity.
Allina Health Sees Early Success From Voice AI in Call Centers - MedCity News
About six months after rolling out voice AI in its call centers, Allina Health is already seeing signs that the tool is doing a good job of improving the patient experience. The technology is reducing patients’ average call times by 5-10 seconds, and 80% of calls are now answered in 45 seconds or less.
Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show - MedCity News
Pfizer drug Braftovi achieved statistically significant and clinically meaningful improvement in overall survival for colorectal cancer patients in a Phase 3 clinical trial. The results will be presented Friday during the annual meeting of the American Society of Clinical Oncology.
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs - MedCity News
May has seen a slew of executive hires, exits and layoffs across the healthcare industry. For example, the American Medical Association and TigerConnect named new CEOs, and Google and UnitedHealth Group have seen key executives leave their roles. There were also layoffs at organizations including Devoted Health and New York-Presbyterian.
Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug - MedCity News
Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy for this target.
Innovate or Stagnate: Overcoming Model Governance Challenges in Life Sciences - MedCity News
By treating model governance as a proactive, integral part of operations rather than a box to check after the fact, life sciences organizations can uphold compliance, better allocate their resources, and gain a competitive edge.